

Abstract number: 4CPS-090 **ATC code**: J05 (Antivirals for systemic use)



Camino del Molino, 2 28942, Fuenlabrada, Madrid, Spain


HEALTH OUTCOMES USING DIRECT-ACTING ANTIVIRAL DRUGS FOR THE TREATMENT OF PATIENTS WITH HEPATITIS C VIRUS AND FO-F1 LIVER FIBROSIS STAGE


María Martín López⁽¹⁾, Belén Hernández Muniesa⁽¹⁾, Ana Ontañón Nasarre⁽¹⁾, Aranzazu Pou Alonso⁽¹⁾, Nuria Herrero Muñoz⁽¹⁾, Mario García Gil⁽¹⁾ ⁽¹⁾Hospital Universitario de Fuenlabrada: Fuenlabrada, Madrid, Spain



Objective

To describe and analyse the effectiveness and safety profiles of DAA drugs in patients with FO-F1 fibrosis stage in a University Hospital.





 \checkmark 3 (1.8%) completed it but were lost to medical follow-up before determining SVR12

- Cephalea: 12.7%
- Gastrointestinal adverse events: 4.8%
- Itching: 4.2%




Discussion

The high effectiveness rates and good safety profiles of DAA allow to treat FO-F1 patients, what may help to eradicate HCV infection, a public health problem.



Conclusion

Our real-world data coroborates clinical trials.



Hepatis C Virus (HCV)

